Takara Bio Inc. (TSE: 4974) is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin(R) reagent, which is a world-standard in gene therapy protocols.

In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed preventing disease and improving the quality of life for all people through the use of biotechnology.

Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. 

Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)